N/A
N=76
The Role of Different Prefrontal Areas in Visual Metacognition
Healthy
Bottom Line
View on ClinicalTrials.gov: NCT04263766 ↗Enrolled (actual)
76
Serious AEs
0.0%
Results posted
Sep 2023
Primary outcome: Primary: Average Confidence Difference With the 0 ms Condition — 0.14; 0.14; 0.14; 0.15 score on a scale (1-4) — p=<.001
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Transcranial magnetic stimulation (Other)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Georgia Institute of Technology
- Primary completion
- Aug 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Average Confidence Difference With the 0 ms Condition |
0.14; 0.14; 0.14; 0.15; -0.01; -0.04 | <.001 sig |
| PRIMARY Average Mratio Difference With the 0 ms Condition |
0.014; 0.087; 0.043; 0.070; -0.211; -0.170 | >0.19 |
Summary
The study will use transcranial magnetic stimulation (TMS) to investigate the causal role of different brain regions during visual perception. TMS is a well-established technique used by hundreds of labs in the world. The risks associated with the technique are well understood and can be minimized by strict adherence to established safety guidelines. In the proposed study, the investigators will use TMS to specifically address the topic of how metacognitive evaluation is supported by the two prefrontal areas: the dorsolateral prefrontal cortex (DLPFC) and the anterior prefrontal cortex (aPFC). The data will be collected from healthy adults and will ultimately deepen the investigator's understanding of the mechanisms behind the normal processes related to confidence generation and metacognition.
Eligibility Criteria
Inclusion Criteria
- right-handed
- adults 18-40
- with normal or corrected-to-normal vision
Exclusion Criteria
- history of seizures
- family history of epilepsy
- stroke
- severe headaches
- metal anywhere in the head (excluding the mouth)
- cardiac pacemakers
- current use of medication for neurological or psychiatric conditions
Data sourced from ClinicalTrials.gov (NCT04263766). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.